Radek Lakomý

3.8k total citations · 1 hit paper
87 papers, 2.8k citations indexed

About

Radek Lakomý is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Radek Lakomý has authored 87 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 34 papers in Oncology and 28 papers in Cancer Research. Recurrent topics in Radek Lakomý's work include Glioma Diagnosis and Treatment (17 papers), Renal cell carcinoma treatment (16 papers) and Cancer Genomics and Diagnostics (13 papers). Radek Lakomý is often cited by papers focused on Glioma Diagnosis and Treatment (17 papers), Renal cell carcinoma treatment (16 papers) and Cancer Genomics and Diagnostics (13 papers). Radek Lakomý collaborates with scholars based in Czechia, United States and Spain. Radek Lakomý's co-authors include Ondřej Slabý, Eric Van Cutsem, Josep Tabernero, Jana Prausová, Paul Ruff, Vladimir Moiseyenko, Carmen J. Allegra, Guy A. Van Hazel, Marek Svoboda and David Ferry and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Radek Lakomý

75 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Radek Lakomý Czechia	22	1.3k	1.2k	1.0k	806	418	87	2.8k
Dana D. Hu‐Lowe United States	17	1.0k 0.8×	1.8k 1.5×	778 0.7×	798 1.0×	211 0.5×	34	3.0k
Iacopo Petrini Italy	27	1.0k 0.8×	884 0.7×	688 0.7×	723 0.9×	150 0.4×	91	2.5k
Lara Felicioni Italy	26	1.9k 1.5×	1.6k 1.3×	1.4k 1.3×	2.2k 2.8×	173 0.4×	37	3.7k
Francesco Galimi Italy	24	1.2k 0.9×	1.1k 0.9×	458 0.4×	444 0.6×	738 1.8×	35	2.5k
Laura Boldrini Italy	27	916 0.7×	1.2k 1.0×	652 0.6×	733 0.9×	104 0.2×	98	2.5k
Joshua K. Sabari United States	28	2.2k 1.7×	1.0k 0.8×	458 0.4×	1.4k 1.7×	100 0.2×	84	3.0k
Michael Lahn United States	23	1.1k 0.9×	1.3k 1.1×	400 0.4×	264 0.3×	175 0.4×	42	2.2k
Baojin Fu United States	12	2.2k 1.7×	1.2k 1.0×	1.4k 1.4×	699 0.9×	81 0.2×	13	3.5k
James Suh United States	21	1.0k 0.8×	519 0.4×	577 0.6×	820 1.0×	179 0.4×	72	1.9k
Hideharu Kimura Japan	26	1.4k 1.1×	825 0.7×	742 0.7×	1.5k 1.9×	111 0.3×	113	2.6k

Countries citing papers authored by Radek Lakomý

Since Specialization

Citations

This map shows the geographic impact of Radek Lakomý's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radek Lakomý with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radek Lakomý more than expected).

Fields of papers citing papers by Radek Lakomý

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radek Lakomý. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radek Lakomý. The network helps show where Radek Lakomý may publish in the future.

Co-authorship network of co-authors of Radek Lakomý

This figure shows the co-authorship network connecting the top 25 collaborators of Radek Lakomý. A scholar is included among the top collaborators of Radek Lakomý based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radek Lakomý. Radek Lakomý is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kopecký, Jindřich, et al.. (2024). The outcome in patients with BRAF‐mutated metastatic melanoma treated with anti‐programmed death receptor‐1 monotherapy or targeted therapy in the real‐world setting. Cancer Medicine. 13(5). e6982–e6982. 4 indexed citations

Selingerová, Iveta, Radek Lakomý, Alexandr Poprach, et al.. (2024). Early changes of peripheral circulating immune subsets induced by PD-1 inhibitors in patients with advanced malignant melanoma and non-small cell lung cancer. BMC Cancer. 24(1). 1590–1590. 1 indexed citations

Hendrych, Michal, P. Solar, Markéta Hermanová, et al.. (2023). Spinal Metastasis in a Patient with Supratentorial Glioblastoma with Primitive Neuronal Component: A Case Report with Clinical and Molecular Evaluation. Diagnostics. 13(2). 181–181. 4 indexed citations

Poprach, Alexandr, Igor Kišš, Michal Staník, et al.. (2023). Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. Targeted Oncology. 18(6). 893–903. 3 indexed citations

Staník, Michal, et al.. (2021). Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy. Urologic Oncology Seminars and Original Investigations. 40(3). 111.e27–111.e34.

Poprach, Alexandr, Radek Lakomý, Michal Staník, et al.. (2019). Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database. Urologic Oncology Seminars and Original Investigations. 37(4). 294.e1–294.e8. 5 indexed citations

Kazda, Tomáš, Radek Lakomý, Petr Pospíšil, et al.. (2019). Current approaches to the radiotherapy of brain metastases from solid tumors. 13(4). 167–172. 1 indexed citations

Kazda, Tomáš, Petr Burkoň, Petr Pospíšil, et al.. (2018). Radiotherapy of glioblastoma 15 years after the landmark Stupp’s trial: more controversies than standards?. Radiology and Oncology. 52(2). 121–128. 45 indexed citations

Poprach, Alexandr, Radek Lakomý, & Tomáš Büchler. (2017). Immunotherapy of Renal Cell Carcinoma. Klinicka onkologie. 30(Suppl 3). 3S55–3S61. 10 indexed citations

10.

Büchler, Tomáš, Alexandr Poprach, Zbyněk Bortlíček, et al.. (2017). Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer. Clinical Genitourinary Cancer. 15(6). e1047–e1053. 8 indexed citations

11.

Lakomý, Radek, Alexandr Poprach, Zbyněk Bortlíček, et al.. (2017). Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer. 17(1). 880–880. 9 indexed citations

12.

Poprach, Alexandr, Radek Lakomý, Zbyněk Bortlíček, et al.. (2016). Efficacy of Sunitinib in Elderly Patients with Metastatic Renal Cell Carcinoma: Data from Real-World Clinical Practice. Drugs & Aging. 33(9). 655–663. 15 indexed citations

13.

Staník, Michal, et al.. (2016). Neoadjuvantní chemoterapie u invazivních uroteliálních nádorů měchýře: korelace léčebné odpovědi a přežití pacientů. 20(3). 221–228.

14.

Poprach, Alexandr & Radek Lakomý. (2016). Renal carcinoma and immunotherapy. 10(6). 251–255. 1 indexed citations

15.

Lakomý, Radek, et al.. (2016). Risk adapted treatment in clinical stage I. non-seminomatous germ cell tumours. 10(4). 193–195.

16.

Poprach, Alexandr, Zbyněk Bortlíček, Bohuslav Melichar, et al.. (2015). Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency. European Journal of Cancer. 51(4). 507–513. 10 indexed citations

17.

Ferry, David, Paul Ruff, Radek Lakomý, et al.. (2013). Time Course of Adverse Events in the Velour Trial. Annals of Oncology. 24. iv36–iv36. 1 indexed citations

18.

Cutsem, Eric Van, Josep Tabernero, Radek Lakomý, et al.. (2012). Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology. 30(28). 3499–3506. 986 indexed citations breakdown →

19.

Lakomý, Radek, Pavel Fadrus, Pavel Šlampa, et al.. (2011). Výsledky multimodální léčby glioblastoma multiforme:konsekutivní série 86 pacientů diagnostikovaných v letech2003–2009. Klinicka onkologie. 24(2). 1 indexed citations

20.

Cutsem, Eric Van, Josep Tabernero, & Radek Lakomý. (2011). Intravenous (IF) Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCC): Results of a multinational phase III trial (EFC10262-VELOUR). Annals of Oncology. 22. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact